INDUSTRIAL IMPACT

ADM Further Expands Microbial Science and Technology Innovation Capabilities with Investment in Precision Fermentation Leader Acies Bio

ADM | October 22, 2021

ADM a global leader in nutrition and agricultural origination and processing, annoThis investment will help ADM more quickly advance projects in the field of precision microbial fermentation by leveraging Acies Bio’s extensive microbial capabilities and contract manufacturing services.

Microbial technology is unlocking disruptive opportunities in sustainable agriculture, sustainable materials and fuels, and alternative proteins, We’re propelling growth opportunities by working with innovators who appreciate our unique combination of expertise, capacity and access to feedstocks. Now, by investing to become a minority owner in Acies Bio, we’re opening up the door to new collaboration with an innovative, complementary business to meet the growing demand for products developed via microbial fermentation.”

 Ian Pinner, ADM chief strategy and innovation officer.

Founded in 2006, Acies Bio develops innovative, proprietary microbial and synthetic biology-based platforms and technologies and also offers contract R&D services in microbial strain engineering and fermentation for customers in key growth segments, including sustainable agriculture, functional foods and bio-based industrial chemicals.

“Acies Bio’s core mission is to use the nearly unlimited power of microbial diversity to drive disruptive innovation and help create a more sustainable bio-based future,” said Enej Kuščer, Acies Bio's co-founder and director. “This strategic partnership with ADM will allow Acies Bio to expand and accelerate the development of our platform technologies, which aim to replace synthetic chemicals and the often carbon-intensive production currently used in food and agriculture with microbial, bio-based products.”

“This investment from ADM will also allow Acies Bio to expand our infrastructure and increase the high-throughput capabilities of our SmartRoute platform, which will allow faster development of new technologies and products,” said Štefan Fujs, Acies Bio's co-founder and director. “This will speed-up the internal pipeline and also help us deliver more quality services to our partners and collaborators.”

ADM’s investment in Acies Bio is being made through ADM Ventures, the company’s corporate venture capital arm. ADM Ventures invests in cutting-edge start-ups with disruptive technologies across three key areas: human nutrition, animal nutrition and sustainability. ADM Ventures also seeks startups that utilize ADM’s assets and feedstocks to produce sustainable materials, in addition to technologies that enhance the effectiveness or efficiency of ADM’s operations.

About Acies Bio
Acies Bio is a leading European microbial biotechnology company that develops new bioproducts and sustainable production processes for diverse industrial sectors, including pharma, food/feed, agricultural, and industrial biotechnology. With an emphasis on sustainability and using Acies Bio’s unique SmartRoute microbial platform, including synthetic biology and strain engineering, high-throughput screening, precision bioprocess and downstream development, the company has successfully developed and scaled numerous innovative products and precision fermentation technologies with industrial partners worldwide. 

About ADM
At ADM, we unlock the power of nature to provide access to nutrition worldwide. With industry-advancing innovations, a complete portfolio of ingredients and solutions to meet any taste, and a commitment to sustainability, we give customers an edge in solving the nutritional challenges of today and tomorrow. We’re a global leader in human and animal nutrition and the world’s premier agricultural origination and processing company. Our breadth, depth, insights, facilities and logistical expertise give us unparalleled capabilities to meet needs for food, beverages, health and wellness, and more. From the seed of the idea to the outcome of the solution, we enrich the quality of life the world over. 

Spotlight

This lecture on molecular markers summarizes the different types of genetic markers like microsattelite and minisattelite DNA like SSR, ISSR etc. It also explains the structure and the role of these marker DNA.

Spotlight

This lecture on molecular markers summarizes the different types of genetic markers like microsattelite and minisattelite DNA like SSR, ISSR etc. It also explains the structure and the role of these marker DNA.

Related News

CELL AND GENE THERAPY

Tune Therapeutics Launches with Pioneering Epigenomic Control Platform to Master Gene Networks, Treat Broad Range of Diseases

Tune Therapeutics | December 03, 2021

Tune Therapeutics, a biotechnology company pioneering the creation of epi-therapeutic medicines, launched today with its powerful and precise genetic tuning platform, TEMPO. This cutting-edge technology dials gene expression up or down to desired levels – with the potential to reverse pathways of cancer, genetic disease, and aging by changing cell fate and function at will. "Genetic medicine is at a tipping point. We now understand that the driving force of human health and disease is not our genes, but the epigenomic elements that shape and control them. Until now, scientists and bioengineers lacked the combined understanding, clinical expertise, and technology needed to make epigenomic therapies a practical reality. Now, we have all three." Matt Kane, CEO of Tune Therapeutics TEMPO Platform Tune's proprietary TEMPO platform can rapidly target and adjust the epigenomic machinery of the cell, which shapes DNA and controls gene expression. By varying specific control modules in an iterative process, TEMPO can fine-tune expression toward healthy levels – even in diseases involving multiplex or polygenic interactions. Unlike genome editing, the tuning process does not generate double- or single-strand breaks in DNA and makes no permanent changes to the DNA sequence. This de-risks the precise targeting of entire gene networks, allowing Tune to simultaneously turn silenced genes on and dial over-expressed genes down, in a practical, therapeutic context. Tune has already shown that TEMPO can locate epigenomic elements involved in several intractable genetic conditions – revealing targets and networks that would be invisible or inaccessible to gene editing approaches. Moreover, Tune can optimize TEMPO to command expression of individual genes or networks with remarkable specificity and precision. This opens the door to an entirely new class of epi-therapeutics. "The exciting challenge in front of us is taking these transformative advances in technology and extending their potential for our greater society," said Charlie Gersbach, PhD, Acting Chief Scientific Officer, Tune Therapeutics. "From proof of concept in rare, single-gene disorders to common conditions that aren't linked to a single gene mutation – but are treatable through epigenomic control and constitute the vast majority of human diseases." Veteran Genomic Medicine Leadership Team Tune is launching with a veteran leadership team, endowed with deep expertise in gene and cell therapy, genome editing, and epigenetics. Matt Kane, Chief Executive Officer Akira Matsuno, Co-Founder, President and Chief Financial Officer Charlie Gersbach, Ph.D., Co-Founder, Acting Chief Scientific Officer Fyodor Urnov, Ph.D., Co-Founder, Scientific Advisory Board Heidi Zhang, Ph.D., Executive Vice President, Head of Technical Operations Blythe Sather, Ph.D., Vice President, Head of Research In addition, Tune's Board of Directors includes Mr. Kane, Dr. Gersbach, Ali Behbahani, M.D., (New Enterprise Associates), and co-founder Dan McHugh Drawing upon deep, local talent pools in Durham and Seattle, Tune has assembled two highly seasoned discovery and development teams, secured foundational intellectual property from Duke University, and raised $40 million from top-tier investors – including co-leads New Enterprise Associates and Emerson Collective, with Hatteras Venture Partners, Mission BioCapital, and others joining the round. This financing will enable Tune to rapidly advance its preclinical research, attract top-tier talent, and further develop its therapeutic platform. "Tune is effectively pioneering a brand-new therapeutic modality," said Dr. Behbahani. "With the unbound potential of this approach, and their collective successes in the field, Tune is primed to become a transformative presence in modern biomedicine." About Tune Therapeutics Tune Therapeutics, Inc. is orchestrating the power of the epigenome to treat complex, pervasive diseases that have long eluded treatment. With its versatile and powerful TEMPO epigenomic control platform, Tune's experienced team is pioneering a new therapeutic modality that can fine-tune any gene network. In breaking free from the limitations of traditional gene and cell therapies, Tune is developing solutions for even the most challenging and intractable diseases – and building the capacity to transform human health and medicine.

Read More

MEDTECH

Versantis to Present Positive Phase 1b Data at AASLD for VS-01 in Patients with Decompensated Cirrhosis

Versantis | November 15, 2021

Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, announced that positive Phase 1b clinical data from a study of its lead investigational, orphan-designated product, VS-01, in 12 hospitalized patients with decompensated liver cirrhosis will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data show that VS-01 was safe and well tolerated in these patients, and demonstrated promising early indications of efficacy in this clinical study. VS-01 is a potentially lifesaving, multi-organ support therapy that aims to timely reverse Acute-on-Chronic Liver Failure (ACLF) by enhancing the clearance of ammonia and other toxins following paracentesis. The Abstract selected for oral presentation is as follows Oral Presentation Title: Safety and Preliminary Efficacy and Pharmacokinetics of Intraperitoneal VS-01 Infustions in Patients with Decompensated Liver Cirrhosis: A First-in-Human, Open-label, Phase 1b Clinical Trial Presenter: Dr. Frank Erhard Uschner, Section for Translational Hepatology, Department of Internal Medicine I, Goethe University Clinic Frankfurt, Session Date/Time: Monday, November 15, 2021, 12:30 p.m. EST The annual Liver Meeting, held by AASLD, brings together attendees from around the world to exchange the latest research, discuss new developments in treatments, and network with others in the field. The primary objective of this single-center first-in-human study was to evaluate the safety and tolerability of i.p.-administered VS-01 on top of standard of care in cirrhotic patients with ascites and mild hepatic encephalopathy following single and multiple intraperitoneal administrations. The secondary objectives were to gather preliminary PK, PD, and clinical efficacy data. In total, all 12 patients completed treatment in the Department of Internal Medicine I, Goethe University Frankfurt and were assigned to receive either a single dose of VS-01 (Part A; n=9) or four consecutive doses (Part B; n=3). Following the drainage of ascites in these patients, VS-01 was then infused into the peritoneal cavity via the existing paracentesis catheter and removed after a dwell time of 2-3 hours. No treatment-related serious adverse events were reported and no patient discontinued treatment due to an adverse event. VS-01 also demonstrated promising clinical efficacy results, including a high and dose-dependent ammonia clearance, promising improvement in hepatic encephalopathy based on psychometric tests, and increased peritoneal clearance of ACLF-related metabolites. “The data show that VS-01 is safe and well tolerated in cirrhotic patients with ascites and covert (mild) hepatic encephalopathy, so very promising. We were able to administer VS-01 using standard hospital equipment via the therapeutic paracentesis catheter, which we believe can easily be incorporated into standard of care for patients There are very few treatments available for these patients and VS-01 is complementary to those, so we are excited to continue advancing it’s development and hopefully generate the data supporting this ground-breaking clinical approach.” Prof. Dr. Trebicka, the principal investigator and head of the Section of Translational Hepatology in Goethe University Frankfurt “VS-01 represents a promising new therapeutic for the potential treatment of patients with ascites and acute complications of cirrhosis. The data from this early study were very promising and importantly show that VS-01 appears to be safe and well tolerated in these patients. The amomonia and ACLF metabolites clearance data is particularly encouraging,” added Vincent Forster, CEO and co-Founder of Versantis. “The successful completion of this study supports future development of VS-01. We are now preparing to initiate a multi-center Phase 2a study in patients with ACLF, a seriously underserved and under-resourced indication. Together with our pipeline of innovative products, we are committed to developing and commercializing new treatment options for patients suffering from acute liver diseases.” About Acute-on-Chronic Liver Failure (ACLF) ACLF is an underserved medical condition, which, despite best possible available care, is associated with high short-term mortality. It is characterized by an abrupt life-threatening worsening of a pre-existing chronic liver disease (e.g., cirrhosis) resulting in liver and extrahepatic organ failure rapidly progressing into coma and death. Every year at least 150’000 patients are hospitalized with ACLF in the US and EU. The incidence is growing due to a higher prevalence of diabetes, obesity, fatty liver diseases, and alcohol consumption. By timely reversing ACLF and the multi-organ complications arising from cirrhosis, VS-01 aims to improve outcomes in these patients and relieve the growing health and economic burden of this advanced liver disease. About Versantis Versantis is a clinical stage biotechnology company focused on addressing the growing, un-met medical need in liver diseases. With a pipeline of drug and diagnostic products covering chronic and acute indications, Versantis believes it can revolutionize current standard of care for patients suffering from acquired and genetic hepatic deficiencies. Versantis’ lead program, VS-01, is in clinical development as a first-line therapy for the timely reversal of acute-on-chronic liver failure (ACLF). It harnesses Versantis’ proprietary scavenging liposomes to extract toxins from the body and, if approved, will be the first drug to take advantage of the intraperitoneal route to potentially support the liver, kidneys and brain, the organs that most often fail in cirrhotic patients. VS-01 has received orphan drug designation (ODD) from the EMA and U.S. FDA, as well as a Rare Pediatric Diseases Designation from the U.S. FDA for Urea Cycle Disorders. Founded by scientists from ETH Zurich with entrepreneurial drive, Versantis has built a team and Board of seasoned industry executives with a proven ability to advance novel therapies from the idea stage into clinical development. The company is headquartered in Zurich, Switzerland.

Read More

INDUSTRIAL IMPACT

Quantum Genomics Signs an Exclusive License and Production Agreement with Gulf Pharmaceuticals Industries Julphar

Quantum Genomics | December 06, 2021

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will receive exclusive rights to manufacture and market firibastat in the following geographic areas: the MENA1 region, CIS2, Turkey and all other countries on the African continent. With its state-of-the-art manufacturing facilities in the emirate of Ras Al Khaimah, making it possible to mass produce firibastat, Julphar will also be Quantum Genomics’ exclusive supplier for said regions. Quantum Genomics will receive up to $20M in upfront, development and sales milestone payments as well as royalties on future firibastat sales. Julphar has also pledged to invest $2M in Quantum Genomics through a private placement. Details of the transaction will be announced shortly. "Julphar, which was founded forty years ago, is one of the largest pharmaceutical companies in the MENA region. Its success has been built on its comprehensive portfolio including anti-infectives, dermatology and diabetes products and its presence in all key MENA markets. Its business is expanding fast, and cardiology is one of its key areas of investment. Julphar is also among the region’s largest producers and is the ideal partner to support firibastat’s future production needs. We’re already exploring how Julphar could meet some of those requirements for the United States and Europe," Jean-Philippe Milon, CEO of Quantum Genomics Commenting on the agreement, Dr. Essam Mohammed, Julphar’s CEO said: “Julphar is delighted to partner with Quantum Genomics to commercialize firibastat, a first in class molecule to treat resistant and difficult-to-treat hypertension, and to produce it in our state-of-the-art manufacturing facilities in Ras Al Khaimah. We are confident that firibastat will add strong value to the treatment of this unmet medical need and to Julphar’s portfolio.” Dr. Essam Mohammed added: “The new landmark agreement brings together a stronger focus on innovative ways to address critical diseases in the MENA region through manufacturing high-quality medications locally.” About Julphar Julphar is one of the largest pharmaceutical manufacturers in the Middle East and Africa, and for more than four decades, the company has been delivering high quality, innovative and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, Julphar employs 2,500 people and distributes pharmaceutical products to more than 50 countries across the globe. Julphar’s business is centered on three core business units – Julphar Diabetes Solutions, General Medicines and its consumer division, Julphar Life – which target major therapeutic segments including Gastrology, Pain Management, Wound Care, Antibiotics and Cardio-metabolism. Julphar has 13 internationally accredited facilities in the Middle East and Africa. In 2012, Julphar became one of the largest producers of Insulin with its UAE-based biotechnology production unit. About Quantum Genomics Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the Brain Aminopeptidase A Inhibition (BAPAI) mechanism. It is the only company in the world to pursue this innovative approach directly targeting the brain, founded upon more than twenty years of research work by Paris-Descartes University and the INSERM/CNRS laboratory led by Dr. Catherine Llorens-Cortès at the Collège de France. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant hypertension and heart failure.

Read More